OR WAIT 15 SECS
The Healthcare Institute of New Jersey (HINJ) released a new research study showing that New Jersey's life-science industry experienced stable growth in 2007.
Bridgewater, NJ (Aug. 18)-The Healthcare Institute of New Jersey (HINJ) released a new research study showing that New Jersey’s life-science industry experienced stable growth in 2007. The report notes that the global business model of the state’s biopharmaceutical and medical-technology companies faces ongoing challenges. HINJ is a trade association for the research-based pharmaceutical and medical-technology industries in New Jersey.
The report examines the industry’s socioeconomic impact on New Jersey and includes data about employment figures, payroll, expenditures for research and development (R&D), vendor support, state and local tax payments, and donations to New Jersey charities.
The study data for 2007 reveal the following changes from the previous year’s report:
The report’s other findings include the following:
Deloitte conducted the study for HINJ, and it was presented during press conferences at Alpharma (Bridgewater, NJ) and Catalent Pharma Solutions (Moorestown, NJ), two of the HINJ member companies that provided data for the annual survey.